Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645892 | 0.88 | ADRB3 (0.55) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL7570378 | 0.88 | ADRB3 (0.55) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| Oxalic Acid SCHEMBL7571181 | 0.85 | LTA4H (0.62) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL5476693 | 0.81 | ADRB3 (0.55) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL5481516 | 0.81 | LTA4H (0.69) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL5648360 | 0.81 | LTA4H (0.69) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL5485060 | 0.81 | ADRB3 (0.54) | ADRB3ADRB2ADRB1KDM4EALDH1A1 | |
| SCHEMBL5479233 | 0.81 | ADRB3 (0.54) | ADRB3ADRB2ADRB1KDM4EALDH1A1 | |
| SCHEMBL837541 | 0.81 | LTA4H (0.65) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL837542 | 0.81 | LTA4H (0.65) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217724-B2 | Indole, indazole, and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060063762-A1 | Indole indazole and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063762-A1 | Indole indazole and benzazole derivative | ADRB3, ADRA2C, ADRB2 | ADRB3 1/4885LTA4H 3017/4885PLA2G2A 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.